Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

323
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
323
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

213
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
213
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

405
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
405
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

251
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
251
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

208
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
208

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.

Breast cancer research and treatment·2021
Same author

Verily project releases millions of factory-reared mosquitoes.

Nature biotechnology·2018
Same author

Sepsis care bundles: a work in progress.

The Lancet. Respiratory medicine·2018
Same author

Advancing towards precision medicine in ARDS.

The Lancet. Respiratory medicine·2018
Same author

Effect of increasing glucocorticoids on asthma exacerbations.

The Lancet. Respiratory medicine·2018
Same author

CAR T-cells for relapsed B-cell ALL in adults.

The Lancet. Oncology·2018
Same journal

Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study.

The Lancet. Microbe·2026
Same journal

Antiviral suppression and immune memory after nirmatrelvir-ritonavir.

The Lancet. Microbe·2026
Same journal

Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations.

The Lancet. Microbe·2026
Same journal

Strengthening pre-spillover surveillance: the missing link in Ebola preparedness.

The Lancet. Microbe·2026
Same journal

Vaginal microbiota transplantation: from microbial transfer to ecological restoration.

The Lancet. Microbe·2026
Same journal

ESCMID Global Congress 2026.

The Lancet. Microbe·2026
See all related articles

Related Experiment Video

Updated: Sep 23, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.3K

Microbiome therapy for recurrent Clostridioides difficile

Judith A Gilbert

    The Lancet. Microbe
    |May 11, 2022
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
    05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    3.0K
    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.1K

    Related Experiment Videos

    Last Updated: Sep 23, 2025

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
    07:06

    Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

    Published on: December 8, 2014

    27.3K
    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
    05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    3.0K
    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    12:58

    A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

    Published on: May 25, 2017

    9.1K